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SummARy Although the SAPHO (synovitis, acne, pustulosis, hyper-
ostosis, osteitis) syndrome was defined as a distinct entity more than 
20 years ago, its classification within the spectrum of inflammatory 
rheumatic diseases and the proper therapeutic approach are still a 
matter of debate. We present four patients diagnosed with the SAPHO 
syndrome treated and followed-up in our Department, demonstrating 
the diversity of their clinical courses and their responses to different 
therapeutic approaches. We also review the clinical, laboratory, and 
imaging features of the SAPHO syndrome described in the relevant 
literature. Despite the growing quantity of published data on the clini-
cal features of the syndrome and the recognition of two disease pat-
terns (inflammatory and bone remodeling disease), it is still not clear 
whether these possible disease subsets require different therapeutic 
strategies. Tumor necrosis factor-alpha (TNF-α) inhibitors have been 
suggested to be effective in patients with the inflammatory pattern, 
whereas bisphosphonates seem to be effective in patients with bone 
remodeling disease; however, this is still a hypothesis not yet confirmed 
by adequately designed clinical studies. Further research is needed to 
assess disease features predicting favorable response to the two thera-
peutic modalities beyond the first line of therapy – TNF-α inhibitors 
and bisphosphonates. 
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 InTROduCTIOn
The synovitis-acne-pustulosis-hyperostosis-oste-
itis (SAPHO) syndrome is an umbrella term covering 
a number of previously described conditions (1,2). It 
was previously considered to be rare with a preva-
lence of 1/10000 (3), but a Japanese study suggests 
that SAPHO is present in about 4% of patients with 
seronegative spondyloarthropathies (SpA) (4). 
Diagnostic criteria proposed in 1988 (5) have 
not been validated, especially regarding the dis-
tinction from similar conditions, including other 
SpA (Table 1). Neither is it clear whether SAPHO is a 
distinct category within SpA, a subtype of psoriatic 
arthritis, or a primitive autoinflammatory reactive 
osteitis (1,6-8).
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Despite new insights into pathogenesis, the diag-
nostic and therapeutic approach is still based on the 
analogy to SpA and published data of a low level of 
evidence. The variable clinical picture and responses 
to therapy raise the question of the right approach 
to patients with this syndrome and the existence of 
disease subsets requiring different strategies. 
We present four patients with the SAPHO syn-
drome describing different disease courses and ther-
apeutic approaches used (Table 2). We also review the 
heterogeneous clinical presentation of the syndrome 
and the use of each of the available diagnostic tests. 
Finally, we review and discuss the role of therapeutic 
modalities used in the treatment of patients with the 
SAPHO syndrome, focusing on the recognition of two 
disease subsets that possibly respond differently to 
agents beyond the first line of treatment: TNF-α in-
hibitors and bisphosphonates. All patients described 
in this study gave appropriate informed consent.
PATIenTS
Patient 1
A 16-year-old male patient was referred to us in 
August 2010 due to a two-month painful swelling of 
the right jaw angle and recurrent arthralgias of sev-
eral large joints of the extremities. He had a two-year 
history of acne conglobata of the trunk refractory to 
Table 1. Diagnostic criteria for the SAPHO syndrome* 
Inclusion criteria (the presence of one is sufficient for diagnosis)
Osteoarticular manifestations of acne conglobata, acne fulminans, or hidradenitis suppurativa 
Osteoarticular manifestations of palmoplantar pustulosis
Hyperostosis (of the anterior chest wall, limbs, or spine) with or without dermatosis
Chronic recurrent multifocal osteomyelitis involving the axial or peripheral skeleton, with or without dermatosis 
exclusion criteria
Septic osteomyelitis
Infectious chest wall arthritis
Infectious palmoplantar pustulosis
Palmoplantar keratodermia
Diffuse idiopathic skeletal hyperostosis
Osteoarticular manifestations of retinoid therapy
* According to Benhamou et al., 1988 (5)
Table 2. Overview of demographic and disease-related features of four patients with SAPHO syndrome 
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3 F 46 19 <1 ACWb No PPPe Yes No Etretinate, 
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None
4 M 15 <1 3 ACWb No Acne 
conglobata
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doxycycline, azithromycin, and co-amoxiclav. One 
year prior to referral a course of isotretinoin was initi-
ated but discontinued after two weeks due to large 
joint arthralgias. Recurrent arthralgias were partially 
controlled with nonsteroidal antirheumatics (NSAR). 
Several weeks before referral, extraction of the right 
mandibular third molar was performed, without signs 
of purulent inflammation. Co-amoxiclav, clindamycin, 
and metronidazole were administered without effect, 
and the patient developed trismus. The past medical 
history was unremarkable except for a tonsillectomy 
performed in 2002. 
In addition to previous findings, physical examina-
tion revealed bilateral tender submandibular lymph-
adenopathy with prominent acne conglobata of the 
trunk. Laboratory evaluation revealed an elevated 
erythrocyte sedimentation rate (ESR) (53 mm/h, nor-
mal range (NR): 2-12 mm/h), C-reactive protein (CRP) 
(47 mg/L, NR: <5 mg/L), and a raised leukocyte count 
(13.3×109/L, NR: 4.4-11.6×109/L). Results of further 
laboratory workup were unremarkable, including 
coagulation tests, serum and urine biochemistry, uri-
nalysis, serum protein electrophoresis, and immuno-
electrophoresis (serum immunoglobulin classes G, M, 
and A), as well as immunologic tests. The patient was 
HLA B27 negative. 
Mandibular X-ray revealed radiolucency of the 
right mandibular angle and hyperostosis of the 
coronoid process, with adjacent soft tissue swelling. 
A technetium 99m (Tc-99m) bone scan showed a 
marked tracer uptake in the right mandibular angle 
(Figure 1). T1- and T2-weighted magnetic resonance 
imaging revealed a heterogeneous intensity signal 
lesion involving the right mandibular ramus, with 
minimal gadolinium enhancement and periosteal re-
action. The patient was diagnosed with SAPHO and 
treated with a regimen of intravenous pamidronate 
(90 mg at month 0, 45 mg at month 4) with daily per-
oral indomethacin and sulfasalazine. 
Treatment led to reduction of mandibular swell-
ing and acne and to normalization of inflammatory 
markers. Due to non-compliance to peroral therapy 
the patient experienced an aggravation of acne and 
bilateral hip and knee pain. Isotretinoin was added 
to the treatment, and indomethacin was switched 
to ibuprofen. Despite alleviation of acne, arthralgias 
persisted due to ongoing non-compliance to indo-
methacin and sulfasalazine. The patient also devel-
oped recurrent buccal aphthous ulcerations and right 
knee arthritis.  
Lumbar densitometry revealed mild osteopenia 
and the patient developed sideropenia with a nor-
mal blood count. Stool was negative for occult blood 
and testing for serum antiendomysial antibodies was 
negative. The patient refused to undergo further 
evaluation of suspected malabsorption.
Patient 2
A 36-year-old female patient was referred to us 
in June 2002 due to recurring pain in the left gluteus 
and costosternal junctions, which began in 1985 and 
led to progressive impairment of the range of motion 
of the left hip. Since 1987 she had experienced recur-
rent palmoplantar pustulosis (PPP). 
In 1998 the patient was evaluated in another 
department. Examination revealed limited internal 
rotation of the left hip and PPP (clinically and histo-
logically). Laboratory findings were unremarkable, 
except for a polyclonal increase in IgA. Tc-99m bone 
scan revealed intensive uptake in the left sacroiliac 
joint and the left acetabular roof. Computed tomog-
raphy (CT) revealed erosions and sclerosis of the left 
sacroiliac joint and adjacent bones. It also revealed 
narrowing of the left coxofemoral joint with multiple 
Figure 1. Whole-body technetium 99m bone scan of 
a 16-year-old male patient – (a) anterior and (b) pos-
terior view. Increased tracer uptake was observed in 
the right mandibular angle (arrow).
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subchondral transparencies. No symptom relief was 
observed despite treatment with indomethacin. She 
was diagnosed with hyperthyreosis in the context of 
Hashimoto’s thyroiditis and treated successfully with 
thiamazole. 
In 2000 a left supraacetabular bone biopsy re-
vealed marked cortical sclerosis and thickened peri-
osteum. Symptoms were gradually worsening despite 
indomethacin and sulfasalazine, and the patient was 
referred to our Department in June 2002. Laboratory 
tests revealed a slightly elevated ESR (33 mm/h, NR: 2-
12 mm/h), CRP (9.7 mg/L, NR: <5 mg/L), alkaline phos-
phatase (ALP) (160 IU/L, NR: 44-119 IU/L), and total 
serum calcium (2.62 mmol/L, NR: 2.14-2.53 mmol/L). 
Results of further laboratory workup were unremark-
able, and the patient was HLA B27 negative. 
Tc-99m bone scan revealed increased tracer up-
take in the left sternoclavicular joint, sacroiliac joint, 
and hip. Plain X-ray revealed sclerosis with radiolu-
cent zones in the medial portions of both clavicles. 
Pelvic CT findings were similar to those described 
in 1998 (Figure 2). The patient was diagnosed with 
SAPHO. Ineffectiveness of conventional treatment, 
including methylprednisolone, led to a decision to 
introduce intravenous pamidronate: the first appli-
cation (60 mg) was in February 2003, followed by 7 
monthly infusions. This resulted in a transitory relief 
of pain and normalization of inflammatory markers, 
with no effect on skin lesions. A flare of osteoarticular 
symptoms developed thereafter, associated with ele-
vated inflammatory markers but normal levels of ALP 
and IgA. Tc-99m bone scan revealed less intensive up-
take in the left sacroiliac joint and more pronounced 
accumulation in the left hip and both sternoclavicular 
joints. Bisphosphonate treatment was discontinued, 
and total left hip alloplasty was performed in Sep-
tember 2004. Analysis of the femoral head specimens 
revealed features of both acute and chronic SAPHO 
syndrome. Pamidronate was administered again in 7 
monthly infusions from September 2004 to May 2005, 
leading to remission of osteoarticular symptoms. PPP 
was successfully treated with oral methylpredniso-
lone. 
In June 2005, the patient developed arthralgias of 
peripheral joints (radiocarpal, talocrural, and meta-
tarsophalangeal) and symmetric Raynaud syndrome 
of the fingers, without laboratory evidence of in-
flammation. Methotrexate was introduced instead 
of sulfasalazine, helping to control both skin and 
osteoarticular symptoms. In 2006 she developed a 
flare of osteoarticular symptoms with elevated levels 
of urinary N-terminal telopeptide, responding well 
to alendronate. The further disease course was char-
acterized by occasional flares of pain, PPP, episodes 
of Raynaud syndrome, and livedo reticularis of the 
thighs. At present the patient is receiving low-dose 
oral methylprednisolone and weekly methotrexate 
(7.5 mg).
Patient 3
A 46-year-old female patient was referred to us in 
November 2004 due to a 19-year history of recurrent 
palmoplantar pustules and ragades with sternocla-
vicular joint painful swelling. Palmoplantar lesions 
started occuring in 1985. At that time laboratory test 
results were completely normal. Skin biopsy revealed 
pustular psoriasis, and the lesions were treated with 
topical steroids and oral etretinate. No pustular le-
sions have been observed since 1989. 
Meanwhile, the patient developed recurrent bi-
lateral sternoclavicular painful swelling, prominent in 
the left sternoclavicular joint, without signs of neu-
rovascular compression. Laboratory evaluation at our 
Department revealed a slightly elevated ESR (32 mm/
h, NR: 2-12 mm/h). Despite normal levels of total se-
rum ALP, the level of bone ALP isoenzyme was elevat-
ed (41 IU/L, normal values (premenopausal females): 
11.6-29.6 IU/L). Results of other laboratory tests were 
normal and the patient was HLA B27 negative. 
Thoracic X-ray revealed massive osteosclerosis of 
the anterior portions of first ribs with bilateral ster-
noclavicular joint ankylosis. Pelvic X-ray revealed an 
Figure 2. Pelvic computed tomography (CT) of a 36-
year-old female patient revealing ankylosis of the left 
sacroiliac joint, as well as hyperostosis of the adjacent 
sacrum (full arrow) and the left iliac bone (dotted ar-
row) (A – anterior, P – posterior, R – right, L – left). 
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inhomogenous left sacroiliac joint, narrowing of both 
coxofemoral joints, and bilateral iliac crest entesopa-
thy. A Tc-99m bone scan revealed elevated tracer up-
take in both sternoclavicular joints, the sternal manu-
brium, both first ribs, the 5th costosternal junction on 
the right, and both sacroiliac joints. 
The patient was diagnosed with SAPHO syn-
drome. Sulfasalazine and diclofenac were introduced 
but the patient was lost to our follow-up.
Patient 4
An 18-year-old male patient was referred to our 
transitional clinic in June 2013 after being followed-
up at the Department of Pediatrics.
In early 2010 he developed acne of the trunk and 
face, refractory to a prolonged regimen of azithromy-
cin. Six months later he developed anterior muscu-
loskeletal chest pain with unremarkable laboratory 
findings. A Tc-99m bone scan revealed multiple areas 
of tracer uptake in the anterior chest wall, and an 
anterior chest X-ray revealed a mixed lytic-sclerotic 
affection of the sternoclavicular joints. He was diag-
nosed with SAPHO syndrome. Courses of antibiotics 
(macrolides, doxycyclin, and co-amoxiclav), ibupro-
fen, and intravenous pamidronate were administered 
with an unsatisfactory response. Tonsillectomy was 
performed in July 2011 due to recurrent tonsillo-
pharyngitis. A control bone scan revealed intensive 
tracer uptake in the anterior chest wall and both 
humeral heads. Etanercept was introduced, result-
ing with complete relief of osteoarticular symptoms 
after the first application and an unremarkable bone 
scan finding following the third application. Unfortu-
nately, etanercept was stopped due to development 
of a large subcutaneous abscess of the left upper 
arm, successfully treated with intravenous antibiot-
ics: co-amoxiclav and clindamycin. In early 2013 the 
patient was started on methotrexate with an effect 
on both osteoarticular and cutaneous symptoms. 
Physical examination at our clinic revealed acne of 
the anterior trunk. Results of laboratory workup were 
unremarkable, including bacterial cultures of cutane-
ous lesions. A follow-up bone scan revealed normal 
findings in the early static scintigrams and symmetric 
late tracer uptake in both humeral heads. 
dISCuSSIOn
Cutaneous and osteoarticular features of the SA-
PHO syndrome may occur synchronously but more 
often metachronously, causing a delay between dis-
ease onset and diagnosis (9), as demonstrated in our 
patients. Cutaneous affection is not mandatory for di-
agnosis, given that osteitis is the fundamental compo-
nent of the syndrome (9,10). Skin lesions include acne 
fulminans and conglobata, PPP, hydradenitis sup-
purativa, pustular psoriasis, and, according to some 
authors, psoriasis vulgaris and a growing number of 
other neutrophilic dermatoses (8). Osteoarticular fea-
tures comprise osteitis, hyperostosis, synovitis, and 
enthesitis. Related symptoms include inflammatory 
pain and swelling (8). Osteitis is defined as an osteo-
sclerotic reaction with or without osteolysis adjacent 
to a joint, whereas extensive bone formation is termed 
hyperostosis (9). According to some authors, osteitis 
and hyperostosis are perceived as a continuum, with 
osteitis on one end and hyperostosis on the other (11). 
Periosteal thickening and involvement of the adjacent 
soft tissue are prominent in the initial phase (11).
In a study of 120 patients (9), the most commonly 
affected site was the anterior chest wall (63.0%), fol-
lowed by bones adjacent to sacroiliac joints (40.0%) 
and the vertebrae (33.0%). Less frequently affected 
were the mandible (10.8%), the pubic symphisis 
(7.0%) and peripheral bones. Synovitis can develop 
independently or adjacent to osteitis. In the afore-
mentioned study (9), axial arthritis was observed in 
91.9% and peripheral in 36.0% of patients. Peripheral 
arthritis was observed in 2/4 of our patients. Spinal 
lesions include osteosclerosis, spondylitis with or 
without discitis, and syndesmophytes (9). Enthesitis 
was not found in patients with acne and hydradenitis 
suppurativa in a study of 15 SAPHO patients, possibly 
being a factor of distinction between the two disease 
subgroups (12). Mandibular osteitis commonly af-
fects the ascending ramus and the posterior mandib-
ular body, rarely the temporomandibular joint. It may 
present with bruxism and trismus (13), as described 
in Patient 1. 
Chronic recurrent multifocal osteomyelitis is a pe-
diatric condition now considered to be a part of the 
syndrome. In contrast to adults, long bones are com-
monly affected (14).
Several complications were described in the con-
text of the SAPHO syndrome (9,14-20), none of which 
were observed in our patients. SAPHO was also de-
scribed in association with inflammatory bowel dis-
ease (9,21) and multiple sclerosis (13). 
Despite malignant bone disease being the clini-
cally most important differential diagnostic feature, 
it was not included in the list of exclusion diagnos-
tic criteria (5) (Table 1). The differential spectrum of 
the SAPHO syndrome also includes septic arthritis 
and osteomyelitis, osteoarthritis, diffuse idiopathic 
skeletal hyperostosis, Paget’s disease, sarcoidosis, 
mastocytosis, tuberous sclerosis, and Langerhans cell 
histiocytosis (14,22). 
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According to a study of the evolution of the disease, 
more than 50% of patients with the SAPHO syndrome 
had a chronic course (as described in patients from the 
present study), 35% experienced exacerbations and 
remissions, while 13% had a limited course (8).
Despite the proposed criteria, diagnosis is still 
based on clinical judgment. Laboratory workup is of 
limited value: it may reveal elevated inflammatory 
markers (10) and a polyclonal increase in IgA level 
(23).  
Unlike “classical” SpA, HLA B27 was present in only 
3/71 patients evaluated in a large study (8) and 1/4 pa-
tient in our study. The finding of antithyroid antibod-
ies in 20/71 patients failed to be confirmed in another 
study of 90 patients, revealing antinuclear antibodies 
as the most common (24). Conversely, a study of 29 
patients cast doubt on the role of autoimmunity in 
the pathogenesis of the syndrome, revealing no pres-
ence of antinuclear, RF, or CCP antibodies (23). 
Imaging techniques are the cornerstone of the di-
agnostic process, given their ability to detect osteitis 
and hyperostosis. Conventional radiographs are of 
low sensitivity, and CT is the technique of choice (2). 
Nuclear scans are more sensitive, revealing sites of as-
ymptomatic affection. They are a powerful diagnostic 
tool, also useful in patient follow-up, distinguishing 
active from quiescent disease (2,25). Whole body mag-
netic resonance imaging (MRI) and positron emission 
tomography combined with CT (PET/CT) can both 
detect subclinical/silent lesions, offering a greater 
spatial resolution (2). Affected bone sites are shown 
on T1- and T2-weighted imaging as hypointense and 
hyperintense respectively, displaying gadolinium 
enhancement (26), thus suggesting inflammation 
or a tumor. [18F]fluorodeoxyglucose (FDG) PET was 
shown to have a potential role in distinguishing in-
flammation from bony tumors: reported standard up-
take values in inflammatory lesions were lower (27). 
Radiographic features may also aid in distinguishing 
bacterial from SAPHO oste(omyel)itis (11). Ultrasound 
is useful for establishing enthesitis (12).
Although skin biopsy is often performed, bone bi-
opsy is reserved primarily for patients with an atypi-
cal presentation (10,26). Sterile pustules are typically 
found in the skin, whereas bone biopsy reveals two 
different stages. Hallmarks of the acute stage are poly-
morphonuclears, plasma cells, edema, and periostitis, 
whereas fibrosis and bone sclerosis are features of the 
chronic stage (10). Cultures of biopsy specimens are 
usually sterile or reveal atypical microbes, e.g. Propi-
onibacterium acnes (22). 
Despite the growing knowledge of the pathogen-
esis of the SAPHO syndrome, new findings still seem 
to fit in the classically proposed three mechanisms 
molecular mimicry, immune complex deposition, 
and immune barrier breakdown. All of them suggest 
the role of a potential infectious agent (10). 
Treatment of SAPHO syndrome is based on the 
analogy with SpA and still relies on anecdotal reports 
from the literature. The first line of treatment includes 
NSARs and analgesics for osteoarticular symptoms 
and topical therapy for cutaneous lesions. Systemic 
glucocortcoids are an important treatment option, 
as indicated in the study conducted by Colina et al. 
(8), who administered glucocorticoids in 68% of 71 
patients (daily dosage: 10-25 mg of a prednisone 
equivalent). The second line of treatment comprises 
disease modifying antirheumatic drugs – methotrex-
ate, sulfasalazine, leflunomide, cyclosporine, and 
bisphosphonates – but also antibiotics and, less fre-
quently, colchicine and calcitonin (28). The third line 
includes biological drugs, primarily tumor necrosis 
factor-alpha (TNF-α) inhibitors (28). 
The rationale for the use of TNF-α inhibitors is 
based on high levels of TNF-α observed in bone bi-
opsy specimens (29) and recent insights into the role 
of these agents in immune mechanisms in patients 
with SAPHO (23). Infliximab is most commonly used, 
and reported to induce a rapid clinical response in 
16/17 patients, sustained in 13/17 patients (30). In ad-
dition to a positive clinical effect (30-32), etanercept 
has also demonstrated its role on the molecular level 
(23). Successful treatment with adalimumab was also 
described (33). Despite their beneficial effect, TNF-α 
inhibitors may cause aggravation of cutaneous fea-
tures (34), as we have recently reported in our HLA 
B27 negative female patient with anterior chest wall 
osteitis and elevated inflammatory markers treated 
with infliximab (35). We also observed no effect of 
infliximab on the Tc-99m uptake pattern in this pa-
tient, despite regression of osteoarticular complaints 
(35). We also described the occurrence of de novo 
palmoplantar psoriasis, onychodystrophy and IgA 
nephropathy in a rheumatoid arthritis patient treated 
with adalimumab (36). In addition to the previously 
mentioned biological agents, it is noteworthy that 
anakinra showed benefit in the short term in 5/6 pa-
tients with the SAPHO syndrome, including two pa-
tients failing to respond to TNF-α inhibitors (37).  
Bisphosphonates are another promising option 
for the treatment of refractory disease. Apart from 
their effect on bone remodeling, nitrogen-containing 
bisphosphonates also show anti-inflammatory activ-
ity (38,39). Intravenous pamidronate demonstrated a 
favorable effect on osteoarticular and other features 
in 9/10 patients, leading to complete remission in 6/9 
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(40). Despite concerns over its use in children, it led to 
alleviation of symptoms without significant adverse 
effects (41). Successful treatment with other bisphos-
phonates was also reported (42). The spectrum of 
adverse effects seems to differ between intravenous 
and oral bisphosphonates: the first may raise the risk 
of renal disfunction and osteonecrosis of the jaw, and 
the latter may lead to esophagitis (43). 
The decision of whether to start treatment with 
TNF-α inhibitors or bisphosphonates may be influ-
enced by the disease profile: an inflammatory disease 
pattern (morning pain and stiffness, elevated inflam-
matory markers, constitutional symptoms, increased 
early bone scan uptake) may respond favorably to 
TNF-α inhibitors, whereas bisphosphonates may be 
the therapy of choice in patients with marked bone 
remodeling (mandibular affection, elevated serum 
crosslaps, pronounced osteosclerosis, and increased 
late bone scan accumulation) (14,44). This hypothesis 
is yet to be confirmed by adequately designed clinical 
studies.
The idea of antibiotic use for the treatment of the 
syndrome stems from the findings of the Gram posi-
tive anaerobic bacillus Propionibacterium acnes and 
other bacteria in bone biopsy specimens of patients 
with SAPHO (22,45). Other than their antimicrobial ef-
fect, antibiotics have various other immunomodula-
tory effects (46), as described in the case of macrolides 
(47) and co-trimoxazole (48). The use of doxycycline 
and clindamycin was also reported, and long-term 
treatment recommended (49). However, the effect of 
antibiotic treatment is not convincing (22,45). 
Surgery as a treatment option is of limited value 
in patients with the SAPHO syndrome, reserved for 
refractory disease or patients with severe structural 
or functional impairment (50).  
COnCLuSIOn
The SAPHO syndrome is still a diagnostic and 
therapeutic challenge, especially in patients with a 
chronic and/or atypical disease course. There is still 
no clear evidence that identified disease patterns (in-
flammatory and bone remodeling disease) respond 
differently to TNF-α inhibitors and bisphosphonates. 
Further studies are needed to identify disease fea-
tures predictive of a favorable response to each of the 
two medication groups. 
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